Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6298-6307

  Patterson, Andrew W ^a   Wood, Warren J L ^a   Hornsby, Michael ^b   Lesley, Scott ^b   Spraggon, Glen ^b   Ellman, Jonathan A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; ALDEHYDE DERIVATIVE; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CATHEPSIN S INHIBITOR; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; MOLECULAR WEIGHT; PHARMACOPHORE; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CATHEPSINS; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NITRILES; PROTEASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRIAZOLES;

EID: 33750125526     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060701s     Document Type: Article

References (40)

1. Wood, W. J. L.; Patterson, A. W.; Tsuruoka, H.; Jain, R. K.; Ellman, J. A. Substrate Activity Screening: A fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 2005, 127, 15521-15527.
2. Salisbury, C. M.; Ellman, J. A. Rapid identification of potent nonpeptidic serine protease inhibitors. ChemBioChem 2006, 7, 1034-1037.
3. For recent reviews on fragment-based methods, see: (a) Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
4. (b) Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: Leads by design. Drug Discovery Today 2005, 10, 987-992.
5. (c) Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray-crystallography. J. Med. Chem. 2005, 48, 403-413.
6. (a) McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45, 1712-1722.
7. (b) McGovern, S. L.; Helfend, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 2003, 46, 4265-4272.
8. (c) McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: Not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
9. (a) Leroy, V.; Thurairatnam, S. Cathepsin S inhibitors. Expert Opin. Ther. Pat. 2004, 14, 301-311.
10. (b) Yasuda, Y.; Kaleta, J.; Broemme, D. The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics. Adv. Drug Delivery Rev. 2005, 57, 973-993.
11. (c) Leung-Toung, R.; Zhao, Y.; Li, W.; Tam, T. F.; Karimian, K.; Spino, M. Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem. 2006, 13, 547-581.
12. (d) Tully, D. C.; Liu, H.; Alper, P. B.; Chatterjee, A. K.; Epple, R.; Roberts, M. J.; Williams, J. A.; Nguyen, K. T.; Woodmansee, D.; Tumanut, C.; Li, J.; Spraggon, G.; Chang, J.; Tuntland, T.; Harris, J. L.; Karanewsky, D. S. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: Heterocyclic P3. Bioorg. Med. Chem. Lett. 2006, 16, 1975-1980.
13. Gocheva, V.; Zeng, W.; Ke, D.; Klimstra, D.; Reinheckel, T.; Peters, C.; Hanahan, D.; Joyce, J. A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20, 543-556.
14. (a) Rawlings, N. D.; Barrett, A. I. Families of cysteine proteases. Methods Enzymol. 1994, 244, 461-486.
15. (b) Cygler, M.; Mort, J. S. Proregion structure of members of the papain superfamily: Mode of inhibition of enzymic activity. Biochimie 1997, 79, 645-652.
16. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46, 2774-2789.
17. Cogan, D. A.; Liu, G.; Ellman, J. A. Asymmetric synthesis of chiral amines by highly diastereoselective 1,2-additions of organometallic reagents to N-tert-butanesulfinyl imines. Tetrahedron 1999, 55, 8883-8904.
18. Patterson, A. W.; Ellman, J. A. Asymmetric synthesis of α,α-dibranched propargylamines by acetylide additions to N-tert-butane-sulfinyl ketimines. J. Org. Chem. 2006, 71, 7110-7112.
19. Tornoe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057-3064.
20. PDB ID: 2H7J
21. PDB ID: 2HXZ
22. McGrath, M. E. The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct. 1999, 28, 181-204.
23. (a) Russell, R. B.; Barton, G. J. Multiple protein sequence alignment from tertiary structure comparison. Proteins: Struct., Funct., Genet. 1992, 14, 309-323.
24. (b) Barton, G. J. ALSCRIPT: A tool to format multiple sequence alignments. Protein Eng. 1993, 6, 37-40.
25. (a) Bromme, D.; Klaus, J. L.; Okamoto, K.; Rasnick, D.; Palmer, J. T. Peptidyl vinyl sulfones: A new class of potent and selective cysteine protease inhibitors. S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem. J. 1996, 315, 85-89.
26. (b) Marquis, R. W.; James, I.; Zeng, J.; Trout, R. E. L.; Thompson, S.; Rahman, A.; Yamashita, D. S.; Xie, R.; Ru, Y.; Gress, C. J.; Blake, S.; Lark, M. A.; Hwang, S.-M.; Tomaszek, T.; Offen, P.; Head, M. S.; Cummings, M. D.; Veber, D. F. Azepanone-based inhibitors of human cathepsin L. J. Med. Chem. 2005, 48, 6870-6878.
27. (c) Loser, R.; Schilling, K.; Dimmig, E.; Gutschow, M. Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J. Med. Chem. 2005, 48, 7688-7707.
28. Phillips, M. A.; Kaplan, A. P.; Rutter, W. J.; Bartlett, P. A. Transition-state characterization: A new approach combining inhibitor analogues and variation in enzyme structure. Biochemistry 1992, 31, 959-963.
29. Mader, M. M.; Bartlett, P. A. Binding energy and catalysis: The implications for transition-state analogues and catalytic antibodies. Chem. Rev. 1997, 97, 1281-1301.
30. Maly, D. J.; Leonetti, F.; Backes, B. J.; Dauber, D. S.; Harris, J. L.; Craik, C. S.; Ellman, J. A. Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylm-ethylcoumarin (ACC) fluorophore. J. Org. Chem. 2002, 67, 910-915.
31. Lundquist, J. T., IV; Pelletier, J. C. Improved solid-phase peptide synthesis method utilizing α-azide-protected amino acids. Org. Lett. 2001, 3, 781-783.
32. Purity was determined to be >95%, analyzed by HPLC, as described for substrates 8.
33. Krantz, A.; Copp, L. J.; Coles, P. J.; Smith, R. A.; Heard, S. B. Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases. Biochemistry 1991, 30, 4678-4687.
34. Lombard, P. A rapid, safe, and convenient procedure for the preparation and use of diazomethane. Chem. Ind. (London) 1990, 708.
35. Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.; Knight, C. G.; Tamai, M.; Hanada, K. L-trans-Epoxysuccinyl-leucylamido-(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H, and L. Biochem. J. 1982, 201, 189-198.
36. Dixon, M. Determination of enzyme-inhibitor constants. Biochem. J. 1953, 55, 170-171.
37. Vagin, A.; Teplyakov, A. An approach to multi-copy search in molecular replacement. Acta Crystallogr., Sect. D 2000, 56, 1622-1624.
38. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr., Sect. D 2004, 60, 2126-2132.
39. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D 1997, 53, 240-255.
40. Collaborative; Computing; Project; Number 4 The CCP4 suite; Programs for protein crystallography, Version 3.1. Acta Crystallogr., Sect. D 1994, 50, 760-763.